These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance. Rizek C; Fu L; Dos Santos LC; Leite G; Ramos J; Rossi F; Guimaraes T; Levin AS; Costa SF Ann Clin Microbiol Antimicrob; 2014 Sep; 13():43. PubMed ID: 25179208 [TBL] [Abstract][Full Text] [Related]
3. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. Crespo MP; Woodford N; Sinclair A; Kaufmann ME; Turton J; Glover J; Velez JD; Castañeda CR; Recalde M; Livermore DM J Clin Microbiol; 2004 Nov; 42(11):5094-101. PubMed ID: 15528701 [TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Hu YF; Liu CP; Wang NY; Shih SC BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962 [TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data. Karampatakis T; Antachopoulos C; Tsakris A; Roilides E Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1211-1220. PubMed ID: 29644540 [TBL] [Abstract][Full Text] [Related]
6. VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates from Zagreb, Croatia. Bosnjak Z; Bedenić B; Mazzariol A; Jarza-Davila N; Suto S; Kalenić S Scand J Infect Dis; 2010 Mar; 42(3):193-7. PubMed ID: 20001226 [TBL] [Abstract][Full Text] [Related]
7. Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom. Woodford N; Zhang J; Kaufmann ME; Yarde S; Tomas Mdel M; Faris C; Vardhan MS; Dawson S; Cotterill SL; Livermore DM J Antimicrob Chemother; 2008 Dec; 62(6):1265-8. PubMed ID: 18819973 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of the first VIM metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolate in Serbia. Lepsanovic Z; Libisch B; Tomanovic B; Nonkovici Z; Balogh B; Füzi M Acta Microbiol Immunol Hung; 2008 Dec; 55(4):447-54. PubMed ID: 19130752 [TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605 [TBL] [Abstract][Full Text] [Related]
10. Detection and characterization of class A extended-spectrum-beta-lactamase-producing Pseudomonas aeruginosa isolates in Belgian hospitals. Glupczynski Y; Bogaerts P; Deplano A; Berhin C; Huang TD; Van Eldere J; Rodriguez-Villalobos H J Antimicrob Chemother; 2010 May; 65(5):866-71. PubMed ID: 20200037 [TBL] [Abstract][Full Text] [Related]
11. Preferential selection of IMP and VIM metallo-beta-lactamases by imipenem in Pseudomonas aeruginosa. Walsh F; Bracher S; Turner P; Amyes S Chemotherapy; 2007; 53(6):407-9. PubMed ID: 17934261 [TBL] [Abstract][Full Text] [Related]
12. bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Lee K; Lim JB; Yum JH; Yong D; Chong Y; Kim JM; Livermore DM Antimicrob Agents Chemother; 2002 Apr; 46(4):1053-8. PubMed ID: 11897589 [TBL] [Abstract][Full Text] [Related]
13. High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. Chalhoub H; Sáenz Y; Rodriguez-Villalobos H; Denis O; Kahl BC; Tulkens PM; Van Bambeke F Int J Antimicrob Agents; 2016 Dec; 48(6):740-743. PubMed ID: 28128097 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology of metalloenzyme-producing Pseudomonas aeruginosa in a tertiary hospital in Greece. Zappas S; Giakkoupi P; Vourli S; Hadjichristodoulou C; Polemis M; Tzouvelekis LS; Avlami A; Vatopoulos A; Daikos GL; Petrikkos G J Chemother; 2008 Jun; 20(3):307-11. PubMed ID: 18606584 [TBL] [Abstract][Full Text] [Related]
15. [Prevalence of metallo-beta-lactamase in carbapenem resistant Pseudomonas aeruginosa at a university hospital of Buenos Aires City]. Pagniez G; Radice M; Cuirolo A; Rodríguez O; Rodríguez H; Vay C; Famiglietti A; Gutkind G Rev Argent Microbiol; 2006; 38(1):33-7. PubMed ID: 16784133 [TBL] [Abstract][Full Text] [Related]
17. The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre. van der Bij AK; Mol M; van Westreenen M; Goessens WH; Pitout JD Scand J Infect Dis; 2011 Aug; 43(8):596-602. PubMed ID: 21506891 [TBL] [Abstract][Full Text] [Related]
18. Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure. Meletis G; Vavatsi N; Exindari M; Protonotariou E; Sianou E; Haitoglou C; Sofianou D; Pournaras S; Diza E Eur J Clin Microbiol Infect Dis; 2014 Feb; 33(2):253-8. PubMed ID: 24062236 [TBL] [Abstract][Full Text] [Related]
19. Outbreak of Pseudomonas aeruginosa producing IMP-9-type metallo-beta-lactamase in Guangzhou, China. Chao Z; Xiao-Feng W; Dan-Hong S; Jin-Ping Y; Nan-Shan Z Int J Antimicrob Agents; 2008 Oct; 32(4):363-5. PubMed ID: 18619819 [No Abstract] [Full Text] [Related]